BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: McGaughey G, Bayly CI, Cox CD, Schreier JD, Breslin MJ, Bogusky M, Pitzenberger S, Ball R, Coleman PJ. Shaping suvorexant: application of experimental and theoretical methods for driving synthetic designs. J Comput Aided Mol Des 2014;28:5-12. [PMID: 24488306 DOI: 10.1007/s10822-014-9710-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Mcgaughey G, Patrick Walters W. Modeling & Informatics at Vertex Pharmaceuticals Incorporated: our philosophy for sustained impact. J Comput Aided Mol Des 2017;31:293-300. [DOI: 10.1007/s10822-016-9994-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
2 Raheem IT, Breslin MJ, Bruno J, Cabalu TD, Cooke A, Cox CD, Cui D, Garson S, Gotter AL, Fox SV, Harrell CM, Kuduk SD, Lemaire W, Prueksaritanont T, Renger JJ, Stump C, Tannenbaum PL, Williams PD, Winrow CJ, Coleman PJ. Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. Bioorganic & Medicinal Chemistry Letters 2015;25:444-50. [DOI: 10.1016/j.bmcl.2014.12.056] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
3 Cooke RM, Brown AJ, Marshall FH, Mason JS. Structures of G protein-coupled receptors reveal new opportunities for drug discovery. Drug Discovery Today 2015;20:1355-64. [DOI: 10.1016/j.drudis.2015.08.003] [Cited by in Crossref: 105] [Cited by in F6Publishing: 91] [Article Influence: 15.0] [Reference Citation Analysis]
4 Roecker AJ, Cox CD, Coleman PJ. Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. J Med Chem 2016;59:504-30. [PMID: 26317591 DOI: 10.1021/acs.jmedchem.5b00832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 8.9] [Reference Citation Analysis]
5 Habgood M, James T, Heifetz A. Conformational Searching with Quantum Mechanics. In: Heifetz A, editor. Quantum Mechanics in Drug Discovery. New York: Springer US; 2020. pp. 207-29. [DOI: 10.1007/978-1-0716-0282-9_14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hellmann J, Drabek M, Yin J, Gunera J, Pröll T, Kraus F, Langmead CJ, Hübner H, Weikert D, Kolb P, Rosenbaum DM, Gmeiner P. Structure-based development of a subtype-selective orexin 1 receptor antagonist. Proc Natl Acad Sci U S A 2020;117:18059-67. [PMID: 32669442 DOI: 10.1073/pnas.2002704117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
7 Uslaner JM, Herring WJ, Coleman PJ. The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. ACS Pharmacol Transl Sci 2020;3:161-8. [PMID: 32259095 DOI: 10.1021/acsptsci.9b00110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Heifetz A, Chudyk EI, Gleave L, Aldeghi M, Cherezov V, Fedorov DG, Biggin PC, Bodkin MJ. The Fragment Molecular Orbital Method Reveals New Insight into the Chemical Nature of GPCR–Ligand Interactions. J Chem Inf Model 2016;56:159-72. [DOI: 10.1021/acs.jcim.5b00644] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 10.1] [Reference Citation Analysis]
9 Blundell CD, Nowak T, Watson MJ. Measurement, Interpretation and Use of Free Ligand Solution Conformations in Drug Discovery. Elsevier; 2016. pp. 45-147. [DOI: 10.1016/bs.pmch.2015.10.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]